10.1002/ejic.201100464
This research study on the synthesis of actinide(IV) phosphites and phosphates, specifically focusing on thorium(IV), uranium(IV), and neptunium(IV) compounds. The purpose of the study is to understand the behavior of actinides in the environment, particularly in the context of nuclear waste repositories, with a special emphasis on neptunium due to its long half-life and its role in long-term radioactivity. The researchers synthesized three isotypic actinide phosphites, AnIV(HPO3)2(H2O)2 (An = Th, U, Np), and a neptunium(IV) phosphate, Cs[Np(H1.5PO4)(PO4)]2, using mild hydrothermal conditions. They observed that the formation of crystalline products was highly dependent on the solubility of the products and the pH of the starting solutions. The study concluded that solubility is a fundamental property controlling the crystallization of these products, and the source of neptunium and the concentration of phosphite significantly influence the outcome. Chemicals used in the process included UO2(NO3)2·6H2O, Th(NO3)4·4H2O, caesium carbonate, phosphorous acid, and 237NpO2(s), among others.
10.1016/j.bmc.2007.11.030
The research aims to develop a siderophore conjugate that can serve as a potent prostate-specific membrane antigen (PSMA) inhibitor and a potential diagnostic agent for prostate cancer. The study incorporates a semirigid spacer in the conjugate's design to prevent competitive binding between the enzyme inhibitor and the siderophore component, which is crucial for the compound's functionality. The synthesized siderophore conjugate demonstrated potent PSMA inhibitory activity with an IC50 of 4 nM, indicating its potential for detecting prostate-derived cancer cells through magnetic resonance imaging (MRI). Key chemicals used in the research include the siderophore component, the phosphonic acid derivative, and various reagents for the synthesis of the linker and the final conjugate. The study concludes that the designed conjugate retains significant activity despite the extended linker and suggests that further MRI experimental studies on the iron and gadolinium complexes of this compound could pave the way for developing diagnostic agents for prostate cancer and potentially therapeutic agents for selective drug delivery.
10.1016/j.bmc.2008.05.013
The research focuses on the synthesis and evaluation of novel uracil nucleotide derivatives as agonists for the P2Y2 and P2Y6 receptors, which are G protein-coupled receptors activated by nucleotides. The study involves structural modifications of the phosphate, uracil, and ribose moieties of uracil nucleotides to assess their agonist activity at human P2Y2, P2Y4, and P2Y6 receptors. Key modifications include the 2-thio modification, phosphonomethylene bridges for stability, and truncation of dinucleotide agonists. The synthesized compounds were tested for their ability to activate phospholipase C (PLC) in human astrocytoma cells stably expressing the respective P2Y receptors. The experiments utilized various analytical techniques such as NMR, HPLC, and HRMS for compound identification and purity assessment. The main reactants included uracil nucleotides, phosphonic acids, and other chemical modifiers used to synthesize the novel derivatives. The analyses were conducted to determine the EC50 values of the compounds, reflecting their potency in stimulating PLC activity, and to explore structure-activity relationships (SARs).
C
